Resources
Zendo Project
This year, millions of people will use psychedelics outside of supervised medical contexts, many of them for the first time. Taking psychedelics can result in overwhelming and uncomfortable experiences, more likely with high doses, amongst first-time users, and without adequate preparation or setting. Psychedelic harm reduction includes a variety of methods to help prevent and transform difficult experiences while in a non-ordinary state of consciousness.
988
We can all help prevent suicide. The Lifeline provides 24/7, free and confidential support for people in distress, prevention and crisis resources for you or your loved ones, and best practices for professionals in the United States.
Recent Publications
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Clinical research with psychedelics has provided promising positive results for various mental disorders (Andersen et al., 2020; Bahji et al., 2020; Dos Santos et al., 2018; Vargas et al., 2020). However, sample sizes...
How Do Researchers Measure a Psychedelic Trip? The Power of 5D-ASC
The acronym 5D-ASC refers to Five-Dimensional Altered States of Consciousness. This framework offers researchers a powerful tool for analyzing and quantifying subjective experiences encountered during psychedelic journeys. Through careful development and empirical testing, 5D-ASC has emerged.
FDA Grants Accelerated Approval for as a Breakthrough Treatment for Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) granted accelerated approval for Leqembi (lecanemab-irmb) as a groundbreaking treatment. This marks a pivotal moment in the ongoing battle against Alzheimer's, with Leqembi being the second medication approved for the disease designed to tackle its fundamental pathophysiology.